Table 1 Patient, donor and transplant characteristics

From: Evaluation of BM cytomorphology after allo-SCT in patients with MDS

Parameter Results
Males/females (sex ratio) 14:11 (1.3)
Patient age: median (range, years) 58 (28–73)
Date of SCT: median (range) 25/12/2006 (09/02/2005–23/03/2010)
Date of initial diagnosis: median (range) 01/09/2005 (28/01/1993–01/10/2009)
Interval diagnosis—SCT: median (range, months) 8.3 (1.4–144.1)
MDS subtypes (WHO classification) 1
 RA, RT, RN, MDS-U 2 (8%)
 RCMD 3 (12%)
 RARS, RAEB 1 (4%)
 RAEB-1 3 (12%)
 RAEB-2 11 (44%)
 CMML 5 (20%)
Cytogenetic risk group (IPSS) 2
 Favourable (normal KT, -Y alone, 5q alone, 20q alone) 19 (76%)
 Intermediate (other abnormalities) 3 (12%)
 Poor (complex abnormalities: 3, chrom. 7 abnormalities) 3 (12%)
Therapy prior HSCT
 Yes 6 (24%)
 No 19 (76%)
Remission prior HSCT
 CR 1 (4%)
 No CR 5 (20%)
 No therapy 19 (76%)
Donor type
 Unrelated donor 21 (84%)
 Related donor 4 (16%)
Donor sex
 Female 7 (28%)
 Male 18 (72%)
Donor age: median (range, years) 40 (20–66)
HLA matching
 Matched 16 (64%)
 Mismatched 9 (36%)
CMV IgG matching
 Negative donor, positive patient 1 (4%)
 Other combinations 24 (96%)
Conditioning
 MAC 4 (16%)
 RIC 21 (84%)
TBI
 Yes 1 (4%)
 No 24 (96%)
GVHD prophylaxis
 CYA-MTX 8 (32%)
 CYA-MPA 17 (68%)
Acute GVHD
 Grade II 5 (20%)
 Grade III 1 (4%)
 Grade IV 0
 Grade II–IV 6 (24%)
Chronic GVHD
 No 13 (52%)
 Limited 5 (20%)
 Extensive 7 (28%)
Leukocyte engraftment, median (range, days) 11 (9–18)
  1. Abbreviations: CMML=chronic myelomonocytic leukaemia; IPSS=international prognostic scoring system; MAC=myeloablative conditioning; MDS=myelodysplastic syndrome; MDS-U=myelodysplastic syndrome—unclassified; MPA=mycophenolic acid; RA=refractory anaemia; RAEB=refractory anaemia with excess blasts; RARS=refractory anaemia with ring sideroblasts; RCMD=refractory cytopenia with multilineage dysplasia; RIC=reduced intensity conditioning; RN=refractory neutropenia; RT=refractory thrombocytopenia; WHO=World Health Organization.